Paul Harvey

I had hep C for 20 years before I did 48 weeks of combination therapy in 2005. I took it on thinking “don’t worry about the side effects, I’m doing this treatment, I’m not going to worry too much about what happens, I’m just going to do it,” I told myself.

The virus was undetectable within four weeks and I didn’t get any flu-like symptoms or any headaches; the worst side effect I got was constant itching and a subtle downwards mood swing.

I treated the itching with a few different things before I discovered Pinetarsol bath oil. The reclusiveness was harder to notice. I wasn’t doing the things that I usually love to do like spending time with my daughter or surfing.

I do still have some fond memories of my year with combination treatment. I pushed my reclusiveness aside to sail to Hobart on the James Craig tall ship and I have exhilarating memories that will last a lifetime. Treatment also coincided with a time of change. It was linked to the idea that if I got rid of the virus, it would be easier to find someone. Indeed, not long after treatment finished, I met my new partner.

The specialist rang me at work and told me I had relapsed. I sat there, got teary for a minute. I started to tell people, made a few calls, told a few people at work. It was a bit of a slap in the face, but after a few days I was over it. I had given it a shot.

It’s been four years and I am on 48 weeks of a triple therapy trial and all seems to be going well.

People’s perceptions of treatment are sometimes out of whack with the reality. I would definitely encourage people to give it a go. Find out about it and don’t go in blindly but give it a go.

The potential rewards of treatment far outweigh doing nothing.

Share your story now

For people living with a hepatitis condition, it really helps to know they’re not alone. That’s why we’re inviting people to share their stories.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close